Patient with a neurofibromatosis type 1 mutation but a clinical diagnosis of Noonan syndrome

Clinical Dysmorphology

Volumn 21, Issue 4, 2012, Pages 212-214

  Croonen, Ellen A ^a   Yntema, Helger G ^b   Van Minkelen, Rick ^c   Van Den Ouweland, Ans M W ^c   Van Der Burgt, Ineke ^b  

^a Department of Pediatrics ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; CLINICAL FEATURE; CRYPTORCHISM; FACE MALFORMATION; GENE MUTATION; HUMAN; MALE; MULTIPLE MALFORMATION SYNDROME; NEUROFIBROMATOSIS; NOONAN SYNDROME; PLAGIOCEPHALY; PRIORITY JOURNAL;

CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFANT; INFANT, NEWBORN; MUTATION; NEUROFIBROMATOSIS 1; NOONAN SYNDROME;

EID: 84865956079     PISSN: 09628827     EISSN: 14735717     Source Type: Journal    
DOI: 10.1097/MCD.0b013e3283557231     Document Type: Article

References (12)

1. Allanson JE, Hall JG, Van Allen MI (1985). Noonan phenotype associated with neurofibromatosis. Am J Med Genet 21:457-462.
2. Barker D,Wright E, Nguyen K, Cannon L, Fain P, Goldgar D, et al. (1987). Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236:1100-1102.
3. Colley A, Donnai D, Evans DGR (1996). Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 49:59-64.
4. DeBella K, Szudek J, Friedman JM (2000). Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105:608-614.
5. De Luca A, Bottilo I, Sarkozy A, Carta C, Neri C, Bellacchio E, et al. (2005). NF1 gene mutations represent the major molecular event underlying Neurofibromatosis- Noonan syndrome. Am J Hum Genet 77:1092-1101.
6. Martinelli S, De Luca A, Stellacci E, Rossi C, Checqulolo S, Lepri F, et al. (2010). Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 87:250-257.
7. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, et al. (2007). Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signaling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 44:763-771.
8. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. (2010). Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126:746-759.
9. Stumpf DA, Alksne JF, Annegers JF (1988). Neurofibromatosis. Conference statement. Arch Neurol 45:575-578.
10. Thiel C,Wilken M, Zenker M, Sticht H, Fahsold R, Gusek-Schneider GC, Rauch A (2009). Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet 149:1263-1267.
11. Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. (2007). An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 80:140-151.
12. Van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E (1994). Clinical and Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 53:187-191.